Bispecifics continue impressive efficacy streak, but companies look to reduce side effects: #ASH23

SAN DIEGO — Bispecific antibodies from Regeneron, Johnson & Johnson, AbbVie and Roche continue to show impressive efficacy in lymphomas and myeloma based on new trial data presented at the American Society of Hematology’s annual meeting.

However, for some agents, toxicities like cytokine release syndrome remain a substantial concern and…
Click here to view original post

Advertisement — Advertise with Biotech Networks